Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-EN Version v5-FR
Language English French
Date Updated 2022-07-22 2022-07-21
Drug Identification Number 02401320 02401320
Brand name PIPERACILLIN AND TAZOBACTAM FOR INJECTION PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Common or Proper name PIPERACILLIN AND TAZOBACTAM FOR INJECTION PIPERACILLIN AND TAZOBACTAM FOR INJECTION
Company Name HIKMA CANADA LIMITED HIKMA CANADA LIMITED
Ingredients PIPERACILLIN TAZOBACTAM PIPERACILLIN TAZOBACTAM
Strength(s) 3G 0.375G 3G 0.375G
Dosage form(s) POWDER FOR SOLUTION POWDER FOR SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 3.375G VIAL 3.375G VIAL
ATC code J01CR J01CR
ATC description BETA-LACTAM ANTIBACTERIALS, PENICILLINS BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Reason for shortage Requirements related to complying with good manufacturing practices. Requirements related to complying with good manufacturing practices.
Anticipated start date 2022-01-28 2022-01-28
Actual start date
Estimated end date
Actual end date 2022-07-21 2022-07-21
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments To be discontinued. To be discontinued.
Health Canada comments